Fact CheckerSign in

NCT05311956Active, not recruiting

Pain Reduction Using NEurostimulation Study

Delivery of an At-Home Nonpharmacologic Intervention (Transcranial Neurostimulation) to Mitigate Pain in Patients With End Stage Kidney Disease Receiving Hemodialysis

Source: ClinicalTrials.gov · Last updated 15 May 2026

Brief summary (registry, in English)

This is a 4-year project to see if a small battery-powered, device attached to a headband, that sits on the skin surface and delivers what is a hardly noticeable level of electrical stimulation can reduce pain in patients who receive hemodialysis on an ongoing basis.

Status (registry)
Active, not recruiting
Study type
Interventional
Enrollment
125 (estimated)
First submitted
28 Mar 2022
Start date
24 Oct 2022
Primary completion date
28 Jan 2026
Lead sponsor
Weill Medical College of Cornell University
NCT number
NCT05311956

What you commit to

  • Study type: Interventional
  • Planned participants: 125
  • From 24 Oct 2022 to the primary completion date, 28 Jan 2026
  • 2 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Active medical or major psychiatric illnesses that will impact pain or interfere with study procedures
  • History of head trauma, seizure disorder, brain surgery, stroke, or cancer affecting head, metal implants in the head, or compromised skin integrity on the head in the area where electrodes will be placed

Other

  • Use of another neurostimulation device (such as spinal cord stimulator, cardio-stimulator implanted cardioverter-defibrillator)
  • Not able to respond to brief questionnaires and rating scales that will interfere with study procedures
  • Does not tolerate tDCS at a skin test (performed at training Visit 2)
  • Does not provide informed consent
  • \* Does not speak English or Spanish

Who the study is looking for

  • Patients:
  • Age ≥ 21 years
  • Diagnosis of end stage kidney disease (OCD 18.6) and receiving hemodialysis
  • Montreal Cognitive Assessment (MoCA-Blind) adjusted score of≥18;
  • Pain for ≥3 months, with a self-reported pain intensity of ≥4 (on a 0-10 scale) during the week preceding the screening;
  • Speaks English or Spanish
  • Medically stable, as determined by clinician and defined as unlikely to undergo a substantial change in illness or treatment during the next 3 months
  • Able to provide written informed consent.
    • Caregivers:
  • Age ≥21 years
  • Serves as primary caregiver for ESKD patient (e.g., partner, adult child, friend)
  • Speaks English or Spanish

Age in the registry: 21 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (2)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
The Rogosin Institute
Coordinator of this site? Confirm its status
New YorkUnited StatesUnknown status
NewYork-Presbyterian - Weill Cornell Medicine
Coordinator of this site? Confirm its status
New YorkUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.